Fenofibric acid CAS 42017-89-0 procetofenicacid

Model: C17H15ClO4
Place of Origin: Sichuan,China (Mainland)
Brand: MOSINTER
CAS: 42017-89-0
Name: Fenofibric acid
Appearance: White to offwhite crystal powder
Molecular formula: C17H15ClO4
Assay: ≥99%
Melting Point: 176-180°C(lit.)
Molecular weight: 318.75
Storage condition: -20°C Freezer
Alias: 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-propanoicaci

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:50Ton/Year
Min. Order:25 KilogramPacking:According to the...
Means of Transport:Ocean, Air, LandDelivery Date:Within 7 days

Fenofibric acid (CAS: 42017-89-0)


ITEMINDEX
Appearance
White to offwhite crystal powder
Assay≥99%


Fenofibrate (Tricor) is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglycerides level.[1] It is used alone or along with statins in the treatment of hypercholesterolemia andhypertriglyceridemia.

Fenofibrate has been used since 1975, is one of the most commonly prescribed fibrates, and has a well known efficacy and tolerability profile.

Medical uses

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus.It also appears to be helpful in decreasing amputations of the lower legs in this same group of people. Fenofibric acid (CAS: 42017-89-0)


ITEMINDEX
Appearance
White to offwhite crystal powder
Assay≥99%


Fenofibrate (Tricor) is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglycerides level.[1] It is used alone or along with statins in the treatment of hypercholesterolemia andhypertriglyceridemia.

Fenofibrate has been used since 1975, is one of the most commonly prescribed fibrates, and has a well known efficacy and tolerability profile.

Medical uses

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus.It also appears to be helpful in decreasing amputations of the lower legs in this same group of people.

It is used in addition to diet to reduce elevated low-density lipoprotein cholesterol (LDL), total cholesterol, triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL) in adults with primary hypercholesterolemia or mixed dyslipidemia.

  • Severe hypertriglyceridemia type IV or V

  • It is used in addition to diet for treatment of adults with severe hypertriglyceridemia. Improving glycemic control in diabetics showing fasting chylomicronemia will usually decrease the need for pharmacologic intervention.

    Three randomized, double-blind trials have shown that treatment with fenofibric acid plus a statin improved HDL and triglyceride levels better than a statin alone and improved LDL levels better than fenofibric acid monotherapy.

    Additionally, in Europe, fenofibrate is indicated in mixed hyperlipidemia in those with high cardiovascular risk in addition to a statin when triglycerides and HDL are not adequately controlled.

    Contraindications

    Fenofibrate is contraindicated in:

    • Patients with severe renal impairment, including those receiving dialysis (2.7-fold increase in exposure, and increased accumulation during chronic dosing in patients with estimated glomerular filtration rate (eGFR)<30mL/min)

    • Patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function test (LFT) abnormalities

    • Patients with preexisting gallbladder disease

    • Nursing mothers

    • Patients with known hypersensitivity to fenofibrate or fenofibric acid

    Adverse effects

    The most common adverse events (>3% of patients with coadministered statins) are[5]

    • Headache

    • Back pain

    • Nasopharyngitis

    • Nausea

    • Myalgia

    • Diarrhea

    • Upper respiratory tract infection

    Mechanism of action

    "In summary, enhanced catabolism of triglyceride-rich particles and reduced secretion of VLDL underlie the hypotriglyceridemic effect of fibrates, whereas their effect on HDL metabolism is associated with changes in HDL apolipoprotein expression."

    Fenofibrate is a fibric acid derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. It lowers lipid levels by activating Peroxisome proliferator-activated receptor alpha(PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII, which increases lipolysis and elimination of triglyceride-rich particles from plasma.

    PPARα also increases apoproteins AI and AII, reduces very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) containing apoprotein B, and increases high-density lipoprotein (HDL) containing apoprotein AI and AII.

    In addition, by reducing the synthesis and increasing the catabolism of VLDL, fenofibrate increases LDL clearance and reduces small and dense LDL, which are associated with coronary heart disease.Better citation needed

It is used in addition to diet to reduce elevated low-density lipoprotein cholesterol (LDL), total cholesterol, triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL) in adults with primary hypercholesterolemia or mixed dyslipidemia.

  • Severe hypertriglyceridemia type IV or V

  • It is used in addition to diet for treatment of adults with severe hypertriglyceridemia. Improving glycemic control in diabetics showing fasting chylomicronemia will usually decrease the need for pharmacologic intervention.

    Three randomized, double-blind trials have shown that treatment with fenofibric acid plus a statin improved HDL and triglyceride levels better than a statin alone and improved LDL levels better than fenofibric acid monotherapy.

    Additionally, in Europe, fenofibrate is indicated in mixed hyperlipidemia in those with high cardiovascular risk in addition to a statin when triglycerides and HDL are not adequately controlled.

    Contraindications

    Fenofibrate is contraindicated in:

    • Patients with severe renal impairment, including those receiving dialysis (2.7-fold increase in exposure, and increased accumulation during chronic dosing in patients with estimated glomerular filtration rate (eGFR)<30mL/min)

    • Patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function test (LFT) abnormalities

    • Patients with preexisting gallbladder disease

    • Nursing mothers

    • Patients with known hypersensitivity to fenofibrate or fenofibric acid

    Adverse effects

    The most common adverse events (>3% of patients with coadministered statins) are[5]

    • Headache

    • Back pain

    • Nasopharyngitis

    • Nausea

    • Myalgia

    • Diarrhea

    • Upper respiratory tract infection

    Mechanism of action

    "In summary, enhanced catabolism of triglyceride-rich particles and reduced secretion of VLDL underlie the hypotriglyceridemic effect of fibrates, whereas their effect on HDL metabolism is associated with changes in HDL apolipoprotein expression."

    Fenofibrate is a fibric acid derivative, a prodrug comprising fenofibric acid linked to an isopropyl ester. It lowers lipid levels by activating Peroxisome proliferator-activated receptor alpha(PPARα). PPARα activates lipoprotein lipase and reduces apoprotein CIII, which increases lipolysis and elimination of triglyceride-rich particles from plasma.

    PPARα also increases apoproteins AI and AII, reduces very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) containing apoprotein B, and increases high-density lipoprotein (HDL) containing apoprotein AI and AII.

    In addition, by reducing the synthesis and increasing the catabolism of VLDL, fenofibrate increases LDL clearance and reduces small and dense LDL, which are associated with coronary heart disease.Better citation needed



Category: Circulatory System Drugs API

Related Category: Vitamin Preparation API  Psychotropic Drugs API  Endocrine Drugs API  Digestive System Drugs API  Insect Repellent API 


«
Offline Showroom in USA
QR Code